Ajanta Pharma Q2 profit rises 49% to ₹388 crore
In short
Ajanta Pharma reported quarterly net profit of ₹388 crore, up 49%. Revenue rose 33%, and EBITDA was ₹547.6 crore, with margin at 30.5% versus 24.2% last year.
The results point to better operating performance for the drug maker. The report does not state what drove the jump in detail.
What the reporting says
Ajanta Pharma reported a 49% rise in net profit to ₹388 crore for the quarter, with revenue up 33% and EBITDA at ₹547.6 crore. The company’s EBITDA margin expanded to 30.5% from 24.2% a year earlier, according to a publisher summary. The immediate implication is stronger operating performance, but the source does not provide the period, segment mix or management commentary.
Why it matters
Ajanta Pharma reported a 49% rise in quarterly net profit to ₹388 crore, alongside 33% revenue growth and EBITDA of ₹547.6 crore. The EBITDA margin widened to 30.5% from 24.2% in the same period last year, suggesting improved profitability. The reporting does not specify the quarter, the exact drivers of growth, or whether any one business line led the improvement.